Etiology of the metabolic syndrome

Current Cardiology Reviews

Volumn 3, Issue 4, 2007, Pages 232-239

  Fan, Amy Z ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cardiovascular risk factors; Dyslipidemia; Glucose intolerance; Insulin resistance; Metabolic syndrome X; Obesity

Indexed keywords

ENDOCANNABINOID; INSULIN; LEPTIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FAMILY; GENETIC PREDISPOSITION; HORMONE RESISTANCE; HUMAN; HYPERTENSION; HYPOTHESIS; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEPTIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE;

EID: 36249009861     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340307782418389     Document Type: Review

References (139)

1. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
3. Crepaldi G, Nosadini R. Diabetic cardiopathy: is it a real entity? Diabetes Metab Rev 1988; 4: 273-88.
4. Gracey M. New World syndrome in Western Australian aborigines. Clin Exp Pharmacol Physiol 1995; 22: 220-5.
5. Regenauer A. [Prognostic aspects of metabolic syndrome. Is the good living" syndrome regarded seriously enough in general insurance medicine practice?]. Versicherungsmedizin 1996; 48: 161-9.
6. Hopkins PN, Hunt SC, Wu LL, et al. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? Curr Opin Lipidol 1996; 7: 241-53.
7. Ihara Y, Yamada Y, Seino Y. [Multiple risk factor syndrome]. Nippon Rinsho 1999; 57: 2801-5.
8. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanisms of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-54.
9. Groop L, Orho-Melander M. The dysmetabolic syndrome. Journal of Internal Medicine 2003; 250: 105-20.
10. Eriksson J, Taimela S., Koivisto VA. Exercise and the metabolic syndrome. Diabetologia 1997; 40: 125-35.
11. DeFronzo RA, Ferrannini A. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, typertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
12. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-20.
13. Zimmet PZ. Kelly West Lecture 1991. Challenges in diabetes epidemiology-from West to the rest Diabetes Care 1992; 15: 232-52.
14. Camus; JP. [Gout, diabetes, hyperlipemia: a metabolic trisyndrotne]. Rev Rhum Mal Osteoartic 1966; 33: 10-4.
15. Lindblatt U, Langer RD, Wingard DI, et al. Metabolic syndrome and ischemic heart disease in elderly men and women. Am J Epidemiol 2001; 153: 481-9.
16. Bhatheja R, Bhatt DL. Clinical outcomes in metabolic syndrome. J Cardiovasc Nurs 2006; 21: 298-305.
17. Borgman M, McErlean E. What is the metabolic syndrome? Prediabetes and cardiovascular risk. J Cardiovasc Nurs 2006; 21: 285-90.
18. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-74.
19. Ching-Ha Kwan B, Beddhu S. Metabolic syndrome and chronic-kidney disease. Minerva Urol Nefrol 2006; 58: 1-12.
20. Zimmet P, Boyko EJ, Collier GR, et al. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999, 892: 25-44.
21. Marre M, Collet C, Moisan C, et al. [Insulin sensitivity, blood pressure and cardiovascular diseases]. Diabetes Metab 2001; 27: 229-32.
22. Ferrannini E, Haffner SM, Stem MP, et al. High blood pressure and insulin resistance: influence of ethnic background. Eur J Clin Invest 1991; 21: 280-7.
23. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000; 7: 325-31.
24. Hother-Nielsen O, Henriksen JE, Holst JJ, et al. Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 1996; 45: 82-91.
25. Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients' risk. Obes Res 1998; 6, Suppl 1: 8S-17S.
26. Lemieux S. Contribution of visceral obesity to the insulin resistance syndrome. Can J Appl Physiol 2001; 26: 273-90.
27. Festa A, D'Agostino R, Jr., Howard G, et al. Chronic subclinical inflamination as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
28. Arnold AL, Caulin-Glaser TL, Gulanski BI. Insulin resistance explains elevated CRP in diabetics. Circulation 2001; 104(S-II): 834.
29. Ahmad I, Miller M. Elevated C-reactive protein and the insulin resistance syndrome: The sum is greater than the parts. Circulation 2001; 104(S-II): 835.
30. Imperatore G, Riccardi G, Iovine C, et al. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998; 21: 649-54.
31. Juhan-Vage I. Haemostatic parameters and vascular risk. Atherosclerosis 1996; 124: S49-55.
32. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care 2001; 24:1403-10.
33. Erasmus RT, Oyeyinka G, Arije A. Microalbuminuria in noninsulin-dependent (type 2) Nigerian diabetics: relation to glycaemic control, blood pressure and retinopathy. Postgrad Med J 1992; 68: 638-42.
34. Savage S, Estacio RO, Jeffers B, et al. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996; 19: 1243-8.
35. Zavaroni I, Mazza S, Fantuzzi M, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med 1993; 234: 25-30.
36. Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-11.
37. Cigolini M, Targher G, Tonoli M, et al. Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women. Int J Obes Relat Metab Disord 1995; 19: 92-6.
38. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006; 9: 637-42.
39. Lin WY, Yao CA, Wang HC, et al. Impaired lung function is associated with obesity and metabolic syndrome in adults. Obesity (Silver Spring) 2006; 14: 1654-61.
40. Vague J, Vague P, Jubelin J, et al. [Forms of obesity and metabolic disorders]. Verh Dtsch Ges Inn Med 1987; 93: 448-62.
41. Buijs RM, Kreier F. The metabolic syndrome: a brain disease? J Neuroendocrinol 2006; 18: 715-6.
42. Liese AD, Mayer-Davis EJ, Tyroler BA, et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann Epidemiol 1997; 7: 407-16.
43. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
44. NCEP. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
45. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-52.
46. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21: 1-6.
47. Rantala AO, Kauma H, Lilja M, et al. Prevalence of the metabolic syndrome in drag-treated hypertensive patients and control subjects. J Intern Med 1999; 245: 163-74.
48. Reaven GM, Chen YD. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1988; 4: 639-52.
49. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care 1995; 18: 1050-64.
50. Zimmet PZ. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetotogia 1999; 42: 499-518.
51. Mitchell BD, Haffner SM, Hazada HP, et al. The relation between serum insulin levels and 8-year changes in lipid, lipoprotein, and blood pressure levels. Am J Epidemiol. 1992; 136: 12-22.
52. Abe H, Yamada N. Animal models for hyperinsulinemia and insulin resistance. Ann N Y Acad Sci 2000; 902: 134-9.
53. Leyva F, Godsland IF, Ghatel M, et al. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc. Biol 1996; 18: 928-33.
54. Zimmet PZ, Collins VR, de Courten MP, et al. Is there a relationship between leptin and insulin sensitivity independent of obesity? A population-based study in the Indian Ocean nation of Mauritius. Mauritius NCD Study Group. Int J Obes Relat Metab Disord 1998; 22: 171-7.
55. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 2192-5.
56. Zimmet P, Hodge A, Nicolson M, et al. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. BMJ 1996; 313: 965-9.
57. Haffner SM, Miettinen H, Mykkanen L, et al. Leptin concentrations and insulin sensitivity in normoglycermic men. Int J Obes Relat Metab Disord 1997; 21: 393-9.
58. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 99: 2548-56.
59. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic symdrome. Diabetes 2004; 53: 2087-94.
60. Cases JA, Barzilai N. The regulution of body fat distribution and the modulation of insulin action. Int J Obes Relat Metab Disord 2000; 24: S63-6.
61. Barzilai N, Gupta G. Interaction between aging and syndrome X: new insights on the pathophysiology of fat distribution. Ann N Y Acad Sci 1999; 892: 58-72.
62. Benthem,L, Kuipers F, Steffens AB, et al. Excessive portal venous supply of long-chain free fatty acids to the liver, leadtng to hypothalamus-pitaitary-adrenal-axis and sympathetic activation as a key to the development of syndrome X. A proposed concept for the induction of syndrome X. Ann N Y Acad Sci 1999; 892: 308-11.
63. Porte D, Jr. Mechanisms for hyperglycemia in the metabolic syndrome. The key role of beta-cell dysfunction. Ann N Y Acad Sci 1999; 892: 73-83.
64. Pinkney JH, Stehouwer CD, Coppack SW, et al. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: S9-13.
65. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin- dependent diabetes mellitus. Circulation 1993; 88: 2510-6.
66. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
67. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-10.
68. Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol 1997; 20: II-26-33.
69. Li-Saw-Hee FL, Blann AD, Lip GY. The detection of endothelial dysfunction in patients with essential hypertension. Int J Cardiol 1997; 61: 171-4.
70. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-5.
71. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
72. Wascher TC. Endothelial transport processes and tissue metabolism: evidence far microvascular endothelial dysfunction in insulin-resistant diseases? Eur J Clin Invest 1997; 27: 831-5.
73. Beckman JA, Goldfine AB, Garrett LA, et al. Insulin resistance is not associated with impaired endothelial function. Circulation 2001; 104(S-II): 151.
74. Naderali EK, Pickavance LC, Wilding JP, et al. Diet-induced endothelial dysfunction in the rat is independent of the degree of increase in total body weight. Clin Sci (Lond) 2001; 100: 635-41.
75. Bjorntorp P, Holm G, Rosmand R, et al. Hypertension and the metabolic syndrome: closely related central origin? Blood Press 2000; 9: 71-82.
76. Bjorntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med 1999; 16: 373-83.
77. Landsberg L. Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome. Ann N Y Acad Sci 1999; 892: 84-90.
78. Stern MP, Gonzalez C, Mitchell BD, et al. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio. Diabetes 1992; 41: 484-92.
79. Liao D, Sloan RP, Cascio WE, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998; 21: 2116-22.
80. Palatini P. Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens 1999; 17: S3-10.
81. Laitinen T, Vauhkonen IK, Niskanen LK, et al. Power spectral analysis of heart rate variability during hyperinsulinemia in nondiabetic offspring of type 2 diabetic patients: evidence for possible early autonomic dysfunction in insulin-resistant subjects. Diabetes 1999; 48: 1295-9.
82. Festa A, D'Agostino R, Jr., Hales CN, et al. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care 2000; 23: 624-8.
83. Lindgren K, Hagelin E, Hansen N, et al. Baroreceptor sensitivity is impaired in elderly subjects with metabolic syndrome and insulin resistance. J Hypertens 2006; 24: 143-50.
84. Escolar G, Diaz-Ricart K Gomez-Gil E, et al. Serotonergic mechanisms: a potential link between affective disorders and cardiovascular risk. Drugs Today (Barc) 2005; 41: 721-43.
85. Muldoon MF, Mackey RH, Williams KV, et al. Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J Clin Endocrinol Metab 2004; 89: 266-71.
86. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
87. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-9.
88. Pi-Sunyer FX, Aronne U, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
89. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 1962. Bull World Health Organ 1999; 77: 694-703.
90. Mitchell BD, Kammerer CM, Mahaney MC, et al. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures. Arterioscler Thromb Vasc Biol 1996; 16: 281-8.
91. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595-601.
92. Power C, Jefferis BJ. Fetal environment and subsequent obesity: a study of maternal smoking. Int J Epidemiol 2002; 31: 413-9.
93. Hong Y, Pedersen NL, Brismar K, et al. Genetic and environmental architecture of the features of the insulin- resistance syndrome. Am J Hum Genet 1997; 60: 143-52.
94. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 2005; 54: 1899-906.
95. Herrick Y, Phillips DI, Haselden S, et al. Maternal consumption of a high-meat, low-carbohydrate diet in late pregnancy: relation to adult cortisol concentrations in the offspring. J Clin Endocrinol Metab 2003; 88: 3554-60.
96. Edwards KL, Newman B, Mayer E, et al. Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol 1997; 14: 241-53.
97. Duggirala R, Blangero J, Almasy L, et al. A major susceptibility locus influencing plasma triglyceride concentrations is located on chromosome 15q in Mexican Americans. Am J Hum Genet 2000; 66: 1237-45.
98. Edwards KL, Mahaney MC, Motulsky AG, et al. Pleiotropic genetic effects on LDL size, plasma triglyceride, and HDL cholesterol in families. Arterioscler Thromb Vaac Biol 1999; 19: 2456-64.
99. Mitchell BD, Almasy LA, Rainwater DL, et al. Diabetes and hypertension in Mexican American families: relation to cardiovascular risk. Am J Epidemiol 1999; 149: 1047-56.
100. Stewart MW, Humphriss DB, Berrish TS, et al. Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care 1995; 18: 1020-2.
101. Gulli G, Ferrannini E, Stern M, et al. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992; 41: 1575-86.
102. Elbein SC, Maxwell TM, Schumacher MC. Insulin and glucose levels and prevalence of glucose intolerance in pedigrees with multiple diabetic siblings. Diabetes 1991; 40: 1024-32.
103. Ho LT, Chang ZY, Wang JT, et al. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med 1990; 7: 31-4.
104. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin- dependent diabetes mellitus. N Engl J Med 1989; 321: 337-43.
105. Laws A, Stefanick ML, Reaven GM. Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989; 69: 343-7.
106. Haffner SM, Stern MP, Hazuda HP, et al. Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 1988; 319: 1297-301.
107. Poulsen P, Vaag A, Kyvik K, et al. Genetic versus environmental aetiology of the metabolic syndrome among male and female twins. Diabetologia 2001; 44: 537-43.
108. Carmelli D, Cardon LR, Fabsitz R. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments? Am J Hum Genet 1994; 55: 566-73.
109. Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-94.
110. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316: 1331-6.
111. Ukkola O, Bouchard C. Clustering of metabolic abnormalities in obese individuals: the role of genetic factors. Ann Med 2001; 39: 79-90.
112. Nestel P. Metabolic syndrome: multiple candidate genes, multiple environmental factors-multiple syndromes? Int J Clin Pract Suppl 2003: 3-9.
113. Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med 2006; 3: 482-9.
114. Sale MM, Woods J, Freedman BI. Genetic determinants of the metabolic syndrome. Curr Hypertens Rep 2006; 8: 16-22.
115. Nisura R, Banks SM, Ward KD, et al. Hostility and the metabolic syndrome in older males: the normative aging study. Psychosom Med 2000; 62: 7-16.
116. Mesch VR, Boero LE, Siseles NO, et al. Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. Climacteric 2006; 9: 40-8.
117. Mugo M, Sowers JR. Metabolic syndrome: implications of race and ethnicity. Ethn Dis 2004; 14: S2-26-31.
118. Procopiou M, Philippe J. The metabolic syndrome and type 2 diabetes: epidemiological figures and country specificities. Cerebrovasc Dis 2005; 20(Suppl. 1): 2-8.
119. Hopkinson ZE, Sattar N, Fleming R, et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 1998; 317: 329-32.
120. Korhonen S, Hippelainen M, Vanhala M, et al. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 2003; 79: 1327-34.
121. Golden SH, Ding J, Szklo M, et al. Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism i n postmenopausal women: the atherosclerosis risk in communities study. Am J Epidemiol 2004; 160: 540-8.
122. Kang H, Greenson JK, Omo JT, et al. Metabolic Syndrome Is Associated with Greater Histologic Severity, Higher Carbohydrate, and Lower Fat Diet in Patients with NAFLD. Am J Gastroenterol 2006; 101: 2247-53.
123. Williams DE, Prevost AT, Whichelow MJ, et al. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. Br J Nutr 2000; 83: 257-66.
124. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol 2006; 48: 677-85.
125. Baxter AJ, Coyne T, McClintock C. Dietary patterns and metabolic syndrome-a review of epidemiologic evidence. Asia Pac J Clin Nutr 2006; 15: 134-42.
126. Chan JC, Cheung JC, Lau EM, et al. The metabolic syndrome in Hong Kong Chinese. The interrelationships among its components analyzed by structural equation modeling. Diabetes Care 1996; 19: 953-9.
127. Hunt KJ, Heiss G, Sholinsky PD, et al. Familial history of metabolic disorders and the multiple metabolic syndrome: the NHLBI family heart study. Genet Epidemiol 2000; 19: 395-409.
128. Tahtinen TM, Vanhala MJ, Oikarinen JA, et al. Effect of smoking on the prevalence of insulin resistance-associated cardiovascular risk factors among Finnish men in military service. J Cardiovasc Risk 1998; 5: 319-23.
129. Kiechl S, Willeit J, Poewe W, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ 1996; 313: 1040-4.
130. Yamada Y, Noborisaka Y, Suzuki H, et al. Alcohol consumption, serum gamma-glutamyltransferase levels, and coronary risk factors in a middle-aged occupational population. J Occup Health 2003; 45: 293-9.
131. Carroll S, Cooke CB, Butterly RJ. Metabolic clustering, physical activity and fitness in nonsmoking, middle-aged men. Med Sci Sports Exerc 2000; 32: 2079-86.
132. Leineweber C, Kecklund G, Akerstedt T, et al. Snoring and the metabolic syndrome in women. Sleep Med 2003; 4: 531-6.
133. Sasanabe R, Banno K, Otake K, et al. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens Res 2006; 29: 315-22.
134. Pickering T. Cardiovascular pathways: socioeconomic status and stress effects on hypertension and cardiovascular function. Ann N Y Acad Sci 1999; 896: 262-77.
135. Wamala SP, Lynch J, Horsten M, et al. Education and the metabolic syndrome in women. Diabetes Care 1999; 22: 1999-2003.
136. Brunner EJ, Marmot MG, Nanchahal K. et al. Social inequality in coronary risk: central obesity and the metabolic syndrome. Evidence from the Whitehall II study. Diabetologia 1997; 40: 1341-9.
137. Vitaliano PP, Scanlan JM, Zhang J, et al. A path model of chronic stress, the metabolic syndrome, and coronary heart disease. Psychosom Med 2002; 64: 418-35.
138. Phillips C, Lopez-Miranda J, Perez-Jimenez F, et al. Genetic and nutrient determinants of the metabolic syndrome. Curr Opin Cardiol 2006; 21: 185-93.
139. Leonard BE. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 2005; 20(Suppl. 3): S302-6.